Ascletis
About
Ascletis is a specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases.
- 251 - 500
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $100M
- Industries
- Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2011
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 3, 2017 | Series B | $100M | 2 | — | — | Detail |
| Apr 6, 2011 | Series A | $100M | 1 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
|
— | Series B |
|
|
— | Series B |
